ISO 9001:2015 Certified WHO-GMP PCD Pharma Franchise Company in India300+ Products Monopoly Rights Pan India DistributionCall us: +91-86533 91199

Product List

Home / ARPOD-CV DRY SYP

MOXYM-CV 625

Product Packing: 10X1X10

Product Composition: Amoxycillin 500 mg + Potassium Clavulanate 125 mg

Product Price: MRP : 1967.7

MOXYM-CV 625 Tablets

Amoxycillin 500 mg + Potassium Clavulanate 125 mg Tablets

MOXYM-CV 625 is a prescription antibacterial combination containing Amoxycillin 500 mg and Potassium Clavulanate 125 mg. Amoxycillin is an aminopenicillin beta-lactam antibiotic, while clavulanate inhibits selected bacterial beta-lactamases and can help protect Amoxycillin from enzymatic inactivation.

Amoxycillin inhibits bacterial cell-wall synthesis by binding to penicillin-binding proteins. Clavulanate acts as a beta-lactamase inhibitor, extending activity against selected beta-lactamase-producing susceptible organisms. Treatment should follow appropriate diagnosis, approved prescribing information and antimicrobial-stewardship principles.

Composition

Each tablet contains:

· Amoxycillin - 500 mg

· Potassium Clavulanate - 125 mg

· Excipients - q.s.

Dosage form: Tablet

Pack size: 10 x 1 x 10 tablets

Uses of MOXYM-CV 625

MOXYM-CV 625 may be prescribed for selected bacterial infections caused by susceptible organisms where Amoxycillin with Clavulanate therapy is approved and clinically appropriate.

· Treatment of selected ear, nose, throat and respiratory-tract bacterial infections according to approved prescribing information

· Treatment of selected urinary-tract bacterial infections caused by susceptible organisms

· Treatment of selected skin, soft-tissue, dental or other bacterial infections where this combination is indicated

· Other approved susceptible bacterial infections as determined by the treating clinician

This combination does not treat viral infections such as the common cold or influenza. Unnecessary or inappropriate antibiotic use contributes to antimicrobial resistance.

How MOXYM-CV 625 Works

MOXYM-CV 625 combines a beta-lactam antibacterial with a beta-lactamase inhibitor:

Amoxycillin: Binds to bacterial penicillin-binding proteins and inhibits peptidoglycan cross-linking during cell-wall synthesis.

Potassium Clavulanate: Inhibits selected beta-lactamase enzymes that could otherwise inactivate Amoxycillin.

Combined activity: This can restore or extend Amoxycillin activity against selected susceptible beta-lactamase-producing organisms.

Clinical response depends on infection site, organism susceptibility, dose, treatment duration and individual patient factors.

Dose selection and treatment duration must follow the approved product label and prescribing clinician's advice.

Dosage and Direction for Use

Use MOXYM-CV 625 exactly as prescribed. Dose, frequency and duration depend on the diagnosed infection, age, kidney function, clinical response and other patient factors.

Take the tablet at the time and frequency directed by the prescriber. Administration at the start of a meal is commonly recommended for Amoxycillin-Clavulanate formulations to improve gastrointestinal tolerability and optimize clavulanate absorption; follow the approved label.

Take doses at appropriately spaced intervals as directed. If a dose is missed, follow the approved label or prescriber's advice and do not double doses unless specifically instructed.

Complete the prescribed antibiotic course unless the treating healthcare professional advises otherwise. Renal impairment may require dose or interval adjustment.

Possible Side Effects

· Possible unwanted effects may include:

· Diarrhoea, nausea, vomiting or abdominal discomfort

· Skin rash, itching, urticaria or candidiasis

· Headache or other mild gastrointestinal symptoms can occur

· Rare but serious effects can include severe allergic reactions, severe skin reactions, significant liver injury or antibiotic-associated diarrhoea including C. difficile-associated disease

· Seek urgent medical attention for breathing difficulty, facial or throat swelling, severe rash, jaundice, severe weakness or persistent or bloody diarrhoea.

Persistent or troublesome adverse effects should be discussed with the treating healthcare professional.

Precautions and Contraindications

Before using MOXYM-CV 625, the prescriber should review penicillin or cephalosporin allergy, kidney and liver function, previous Amoxycillin-Clavulanate-associated jaundice or hepatic dysfunction, and all concomitant medicines.

· Do not use in patients with known serious hypersensitivity to Amoxycillin, clavulanate, penicillins or formulation ingredients according to approved prescribing information.

· A history of cholestatic jaundice or hepatic dysfunction associated with previous Amoxycillin-Clavulanate therapy is an important contraindication according to approved prescribing information.

· Use caution in significant renal impairment because dose or dosing interval adjustment may be necessary.

· Liver-related adverse effects can occur; clinical assessment and monitoring may be appropriate in patients with hepatic risk factors or prolonged treatment.

· Antibiotic-associated diarrhoea, including C. difficile-associated disease, can occur during or after antibacterial treatment.

· Pregnancy, breastfeeding, children, older adults and patients with significant chronic conditions require individualized professional guidance.

· Keep out of reach of children and store according to the approved pack instructions.

· Drug Interaction Considerations

· Clinically relevant interaction considerations may include anticoagulants, allopurinol, probenecid, methotrexate and other medicines. The significance depends on the patient's regimen and clinical circumstances.

· Patients should provide the prescriber with a complete list of prescription medicines, OTC products, vitamins, minerals and supplements before starting MOXYM-CV 625.

Business Growth Opportunity with MOXYM-CV 625

MOXYM-CV 625 offers pharmaceutical distributors and healthcare entrepreneurs an opportunity to add an Amoxycillin 500 mg + Potassium Clavulanate 125 mg prescription antibacterial tablet to their anti-infective product portfolio.

Amoxycillin-Clavulanate is an established antibacterial combination. Promotion and use should support antimicrobial stewardship and remain strictly consistent with approved product information and applicable pharmaceutical regulations.

Key Business Advantages

· Dual-component beta-lactam antibacterial formulation

· Amoxycillin 500 mg + Potassium Clavulanate 125 mg

· Combines an aminopenicillin with a beta-lactamase inhibitor

· Convenient tablet dosage form

· Suitable addition to anti-infective prescription portfolios where this combination is clinically appropriate

· Opportunity for ethical, stewardship-conscious promotion through appropriate healthcare channels

PCD Pharma Franchise Opportunity for MOXYM-CV 625

Ethics Medinova Private Limited offers PCD Pharma Franchise opportunities for MOXYM-CV 625 in selected territories across India, subject to availability, applicable regulations and mutually agreed business terms.

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

Franchise Support May Include

· Monopoly-based territory opportunities, subject to availability

· Promotional materials and visual aids

· Product information and marketing support

· Reliable supply coordination

· Access to a growing pharmaceutical product portfolio

· Professional partner assistance

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for MOXYM-CV 625 and other quality-focused healthcare products.

Third-Party Manufacturing Support for Amoxycillin 500 mg + Potassium Clavulanate 125 mg Tablets

Ethics Medinova also supports eligible businesses exploring third-party manufacturing of formulations similar to MOXYM-CV 625 under their own brand, subject to applicable licensing, prescription-drug, regulatory and manufacturing requirements.

Our third-party manufacturing support may include:

· Customized product and pack requirements, subject to regulatory feasibility

· Private-label manufacturing opportunities

· Customized packaging and branding support

· Product label and pack configuration assistance

· Manufacturing coordination through suitable licensed facilities

· Support for documentation and applicable regulatory requirements

This service may be suitable for eligible pharmaceutical companies and healthcare brands seeking to expand an anti-infective prescription product portfolio.

Frequently Asked Questions About MOXYM-CV 625

1. What is MOXYM-CV 625?

MOXYM-CV 625 is a tablet formulation containing Amoxycillin 500 mg and Potassium Clavulanate 125 mg.

2. What is MOXYM-CV 625 used for?

It may be prescribed for selected susceptible bacterial infections where Amoxycillin-Clavulanate therapy is approved and clinically appropriate.

3. How should MOXYM-CV 625 be taken?

Take MOXYM-CV 625 exactly as prescribed. Follow the approved label regarding administration with meals and complete the prescribed course unless advised otherwise.

4. What is the role of Clavulanate?

Clavulanate inhibits selected bacterial beta-lactamases, helping protect Amoxycillin from enzymatic inactivation in susceptible organisms.

5. Can people with penicillin allergy take MOXYM-CV 625?

A history of penicillin or other beta-lactam allergy must be discussed with the prescriber. Serious hypersensitivity can occur and may contraindicate use.

6. Are liver precautions important?

Yes. Amoxycillin-Clavulanate can cause liver-related adverse effects, and previous associated cholestatic jaundice or hepatic dysfunction is an important contraindication.

7. Is a PCD Pharma Franchise available for MOXYM-CV 625?

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

8. Can this formulation be manufactured under my own brand?

Eligible businesses interested in a similar Amoxycillin 500 mg + Potassium Clavulanate 125 mg tablet may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing and regulatory requirements.

Disclaimer

MOXYM-CV 625 product information in this document is for general professional and business information. Exact approved composition declaration, indications, dosage, contraindications, warnings, interactions, susceptibility considerations, administration instructions, monitoring requirements, treatment duration, excipients and regulatory status must be verified against the current approved product label and applicable prescribing information before prescribing, dispensing, use or promotion. Antibiotics should be used responsibly under medical supervision to support antimicrobial stewardship. This document is not a substitute for professional medical advice.

Dosage Form

Therapy Wise

MOXYM-CV 625

MOXYM-CV 625 Tablets

Amoxycillin 500 mg + Potassium Clavulanate 125 mg Tablets

Composition

Pack size: 10 x 1 x 10 tablets

This combination does not treat viral infections such as the common cold or influenza. Unnecessary or inappropriate antibiotic use contributes to antimicrobial resistance.

Combined activity: This can restore or extend Amoxycillin activity against selected susceptible beta-lactamase-producing organisms.

Take doses at appropriately spaced intervals as directed. If a dose is missed, follow the approved label or prescriber's advice and do not double doses unless specifically instructed.

· Seek urgent medical attention for breathing difficulty, facial or throat swelling, severe rash, jaundice, severe weakness or persistent or bloody diarrhoea.

· Keep out of reach of children and store according to the approved pack instructions.

· Patients should provide the prescriber with a complete list of prescription medicines, OTC products, vitamins, minerals and supplements before starting MOXYM-CV 625.

Amoxycillin-Clavulanate is an established antibacterial combination. Promotion and use should support antimicrobial stewardship and remain strictly consistent with approved product information and applicable pharmaceutical regulations.

· Opportunity for ethical, stewardship-conscious promotion through appropriate healthcare channels

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for MOXYM-CV 625 and other quality-focused healthcare products.

This service may be suitable for eligible pharmaceutical companies and healthcare brands seeking to expand an anti-infective prescription product portfolio.

Frequently Asked Questions About MOXYM-CV 625

MOXYM-CV 625 is a tablet formulation containing Amoxycillin 500 mg and Potassium Clavulanate 125 mg.

It may be prescribed for selected susceptible bacterial infections where Amoxycillin-Clavulanate therapy is approved and clinically appropriate.

Take MOXYM-CV 625 exactly as prescribed. Follow the approved label regarding administration with meals and complete the prescribed course unless advised otherwise.

Clavulanate inhibits selected bacterial beta-lactamases, helping protect Amoxycillin from enzymatic inactivation in susceptible organisms.

A history of penicillin or other beta-lactam allergy must be discussed with the prescriber. Serious hypersensitivity can occur and may contraindicate use.

Yes. Amoxycillin-Clavulanate can cause liver-related adverse effects, and previous associated cholestatic jaundice or hepatic dysfunction is an important contraindication.

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

Eligible businesses interested in a similar Amoxycillin 500 mg + Potassium Clavulanate 125 mg tablet may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing and regulatory requirements.

Dosage Form

Therapy Wise

MOXYM-CV 625

MOXYM-CV 625 Tablets

Amoxycillin 500 mg + Potassium Clavulanate 125 mg Tablets

Composition

Pack size: 10 x 1 x 10 tablets

This combination does not treat viral infections such as the common cold or influenza. Unnecessary or inappropriate antibiotic use contributes to antimicrobial resistance.

Combined activity: This can restore or extend Amoxycillin activity against selected susceptible beta-lactamase-producing organisms.

Take doses at appropriately spaced intervals as directed. If a dose is missed, follow the approved label or prescriber's advice and do not double doses unless specifically instructed.

· Seek urgent medical attention for breathing difficulty, facial or throat swelling, severe rash, jaundice, severe weakness or persistent or bloody diarrhoea.

· Keep out of reach of children and store according to the approved pack instructions.

· Patients should provide the prescriber with a complete list of prescription medicines, OTC products, vitamins, minerals and supplements before starting MOXYM-CV 625.

Amoxycillin-Clavulanate is an established antibacterial combination. Promotion and use should support antimicrobial stewardship and remain strictly consistent with approved product information and applicable pharmaceutical regulations.

· Opportunity for ethical, stewardship-conscious promotion through appropriate healthcare channels

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for MOXYM-CV 625 and other quality-focused healthcare products.

This service may be suitable for eligible pharmaceutical companies and healthcare brands seeking to expand an anti-infective prescription product portfolio.

Frequently Asked Questions About MOXYM-CV 625

MOXYM-CV 625 is a tablet formulation containing Amoxycillin 500 mg and Potassium Clavulanate 125 mg.

It may be prescribed for selected susceptible bacterial infections where Amoxycillin-Clavulanate therapy is approved and clinically appropriate.

Take MOXYM-CV 625 exactly as prescribed. Follow the approved label regarding administration with meals and complete the prescribed course unless advised otherwise.

Clavulanate inhibits selected bacterial beta-lactamases, helping protect Amoxycillin from enzymatic inactivation in susceptible organisms.

A history of penicillin or other beta-lactam allergy must be discussed with the prescriber. Serious hypersensitivity can occur and may contraindicate use.

Yes. Amoxycillin-Clavulanate can cause liver-related adverse effects, and previous associated cholestatic jaundice or hepatic dysfunction is an important contraindication.

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

Eligible businesses interested in a similar Amoxycillin 500 mg + Potassium Clavulanate 125 mg tablet may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing and regulatory requirements.

We value your privacy

Get the Product Details